114 related articles for article (PubMed ID: 31953242)
1. Newly Synthesized KRAS
Cancer Discov; 2020 Mar; 10(3):341. PubMed ID: 31953242
[No Abstract] [Full Text] [Related]
2. Quantitative Systems Pharmacology Analysis of KRAS G12C Covalent Inhibitors.
Stites EC; Shaw AS
CPT Pharmacometrics Syst Pharmacol; 2018 May; 7(5):342-351. PubMed ID: 29484842
[TBL] [Abstract][Full Text] [Related]
3. Computationally Empowered Workflow Identifies Novel Covalent Allosteric Binders for KRAS
Mortier J; Friberg A; Badock V; Moosmayer D; Schroeder J; Steigemann P; Siegel F; Gradl S; Bauser M; Hillig RC; Briem H; Eis K; Bader B; Nguyen D; Christ CD
ChemMedChem; 2020 May; 15(10):827-832. PubMed ID: 32237114
[TBL] [Abstract][Full Text] [Related]
4. Exploring Targeted Degradation Strategy for Oncogenic KRAS
Zeng M; Xiong Y; Safaee N; Nowak RP; Donovan KA; Yuan CJ; Nabet B; Gero TW; Feru F; Li L; Gondi S; Ombelets LJ; Quan C; Jänne PA; Kostic M; Scott DA; Westover KD; Fischer ES; Gray NS
Cell Chem Biol; 2020 Jan; 27(1):19-31.e6. PubMed ID: 31883964
[TBL] [Abstract][Full Text] [Related]
5. The gRASs Is Greener: Potential New Therapies in Lung Cancer with Acquired Resistance to KRAS
Pinnelli M; Trusolino L
Cancer Discov; 2021 Aug; 11(8):1874-1876. PubMed ID: 34344756
[TBL] [Abstract][Full Text] [Related]
6. Selective apoptosis-inducing activity of synthetic hydrocarbon-stapled SOS1 helix with d-amino acids in H358 cancer cells expressing KRAS
Xu LL; Li CC; An LY; Dai Z; Chen XY; You QD; Hu C; Di B
Eur J Med Chem; 2020 Jan; 185():111844. PubMed ID: 31706640
[TBL] [Abstract][Full Text] [Related]
7. Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor.
Janes MR; Zhang J; Li LS; Hansen R; Peters U; Guo X; Chen Y; Babbar A; Firdaus SJ; Darjania L; Feng J; Chen JH; Li S; Li S; Long YO; Thach C; Liu Y; Zarieh A; Ely T; Kucharski JM; Kessler LV; Wu T; Yu K; Wang Y; Yao Y; Deng X; Zarrinkar PP; Brehmer D; Dhanak D; Lorenzi MV; Hu-Lowe D; Patricelli MP; Ren P; Liu Y
Cell; 2018 Jan; 172(3):578-589.e17. PubMed ID: 29373830
[TBL] [Abstract][Full Text] [Related]
8. The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Fiala O; Pesek M; Finek J; Benesova L; Belsanova B; Minarik M
Cancer Genet; 2013; 206(1-2):26-31. PubMed ID: 23313110
[TBL] [Abstract][Full Text] [Related]
9. An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer.
Wang H; Lv Q; Xu Y; Cai Z; Zheng J; Cheng X; Dai Y; Jänne PA; Ambrogio C; Köhler J
EBioMedicine; 2019 Nov; 49():106-117. PubMed ID: 31668570
[TBL] [Abstract][Full Text] [Related]
10. Can the Help Match the Hype? KRAS
Klempner SJ; Hata AN
Cancer Discov; 2020 Jan; 10(1):20-22. PubMed ID: 31919120
[TBL] [Abstract][Full Text] [Related]
11. Different metabolic responses to PI3K inhibition in NSCLC cells harboring wild-type and G12C mutant KRAS.
Caiola E; Brunelli L; Marabese M; Broggini M; Lupi M; Pastorelli R
Oncotarget; 2016 Aug; 7(32):51462-51472. PubMed ID: 27283493
[TBL] [Abstract][Full Text] [Related]
12. Selective Targeting of the KRAS G12C Mutant: Kicking KRAS When It's Down.
Hobbs GA; Wittinghofer A; Der CJ
Cancer Cell; 2016 Mar; 29(3):251-253. PubMed ID: 26977877
[TBL] [Abstract][Full Text] [Related]
13. Development of a biotin-streptavidin-enhanced enzyme-linked immunosorbent assay (BA-ELISA) for high-throughput screening of KRAS
Liu S; Shi J; Li H; Li J; Zhu Y; Li B; Sun Y
SLAS Discov; 2022 Mar; 27(2):107-113. PubMed ID: 35058184
[TBL] [Abstract][Full Text] [Related]
14. Overcoming Adaptive Resistance to KRAS Inhibitors Through Vertical Pathway Targeting.
Yaeger R; Solit DB
Clin Cancer Res; 2020 Apr; 26(7):1538-1540. PubMed ID: 32001483
[TBL] [Abstract][Full Text] [Related]
15. Heterogeneity and mutation in KRAS and associated oncogenes: evaluating the potential for the evolution of resistance to targeting of KRAS G12C.
Cannataro VL; Gaffney SG; Stender C; Zhao ZM; Philips M; Greenstein AE; Townsend JP
Oncogene; 2018 May; 37(18):2444-2455. PubMed ID: 29453361
[TBL] [Abstract][Full Text] [Related]
16. Researchers Reveal Another KRAS Inhibitor.
Cancer Discov; 2019 Sep; 9(9):1152. PubMed ID: 31387866
[TBL] [Abstract][Full Text] [Related]
17. Identification of novel 3-aryl-1-aminoisoquinolines-based KRAS
Gong Z; Zhao Y; Xu B; Yang Z; Ren B; Yang H; Zeng C; Chen R; Xu YJ; Li Q
Bioorg Chem; 2024 Jan; 142():106954. PubMed ID: 37948926
[TBL] [Abstract][Full Text] [Related]
18. KRAS
Cagir A; Azmi AS
Future Med Chem; 2019 May; 11(9):923-925. PubMed ID: 31140867
[No Abstract] [Full Text] [Related]
19. Mutant KRAS at the Heart of Tumor Immune Evasion.
van Maldegem F; Downward J
Immunity; 2020 Jan; 52(1):14-16. PubMed ID: 31951548
[TBL] [Abstract][Full Text] [Related]
20. Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers.
Hao HX; Wang H; Liu C; Kovats S; Velazquez R; Lu H; Pant B; Shirley M; Meyer MJ; Pu M; Lim J; Fleming M; Alexander L; Farsidjani A; LaMarche MJ; Moody S; Silver SJ; Caponigro G; Stuart DD; Abrams TJ; Hammerman PS; Williams J; Engelman JA; Goldoni S; Mohseni M
Mol Cancer Ther; 2019 Dec; 18(12):2368-2380. PubMed ID: 31439712
[No Abstract] [Full Text] [Related]
[Next] [New Search]
